stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Operating cash flow
Sanofi's operating cash flow for fiscal 2025 was $12.2B, up 23.8% from $9.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $23.8B. Over the past ten years it has ranged from $6.6B (fiscal 2018) to $12.4B (fiscal 2021); the current reading is higher than 91% of that period. Sanofi ranks 3rd of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $12.2B | 23.77% |
| FY2024 | $9.8B | (11.49%) |
| FY2023 | $11.1B | 0.11% |
| FY2022 | $11.1B | (10.91%) |
| FY2021 | $12.4B | 46.30% |
| FY2020 | $8.5B | (1.89%) |
| FY2019 | $8.7B | 32.40% |
| FY2018 | $6.6B | (21.46%) |
| FY2017 | $8.3B | (3.84%) |
| FY2016 | $8.7B | (5.78%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $4.4B | (18.47%) |
| Jun 2026 | $5.4B | (55.61%) |
| Dec 2025 | $12.2B | 564.38% |
| Jun 2025 | $1.8B | (16.98%) |
| 19 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi | $23.8B |
| NVO Novo Nordisk A/S compare | $20.4B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC compare | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
| GSK GSK PLC Sponsored ADR compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement